SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (983)1/3/2002 10:28:13 AM
From: tuck  Respond to of 1784
 
PKI's detection business rode the terrorism wave and was probably behind PKI's foray back into the 30s. PKI, always an M&A (as opposed to internal growth) type of outfit, now cashes it in, which seems wise. Of course, they've got to have some internal growth, and they do, of late mostly from its life sciences business. Their analytical instruments business is pretty tricklish; only their optoelectronics business is not. If memory serves, the latter accounts for substantially less than 50% of revenue. I'll have a closer look when the next quarterly comes out, but I think PKI can be officially declared a trickle company.

>>BOSTON, Jan 3, 2002 (BW HealthWire) -- PerkinElmer, Inc. (NYSE: PKI chart, msgs) announced today the sale of its Detection Systems business to L-3 Communications for approximately $100 million. Detection Systems is a leading supplier of X-ray inspection systems and is expected to generate revenues of more than $80M in 2001. The sale is expected to close in the first quarter of 2001.

Gregory L. Summe, chairman and CEO of PerkinElmer, commented, "This divestiture gives us a very strong balance sheet and leaves us exceptionally well positioned to continue growing our three core businesses - Life Sciences, Optoelectronics and Analytical Instruments."<<

snip

Cheers, Tuck



To: tuck who wrote (983)1/3/2002 1:23:06 PM
From: tom pope  Read Replies (1) | Respond to of 1784
 
Tuck, did you see this?

from Briefing

13:10 ET ABN AMRO on Mass Spec Makers : ABN AMRO is positive on mass spectrometry equipment makers; after BDAL announced strong Q4 orders for its mass spec instruments (see 7:12 comment), firm sees ABI and WAT as beneficiaries of a broad equipment turnaround in 2002 as drug co's increase R&D expenditures; reiterates Buy ratings on ABI and WAT.